Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A Plus Biotechnology CoTPE:6918 74 Debt-to-Equity is 0.14 as of Jun. 2026, which is 8% above its 10-year median of 0.13. GuruFocus rates TPE:6918 with a GF Score™ of 74/100 and a GF Value™ of NT$86.75 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 696 Medical Devices & Instruments companies, A Plus Biotechnology Co ranks better than 63.51% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for A Plus Biotechnology Co's Debt-to-Equity or its related term are showing as below:
TPE:6918'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.13 Max: 0.25
Current: 0.14
During the past 7 years, the highest Debt-to-Equity Ratio of A Plus Biotechnology Co was 0.25. The lowest was 0.05. And the median was 0.13.
TPE:6918's Debt-to-Equity is ranked better than 63.51% of 696
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs TPE:6918: 0.14
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
A Plus Biotechnology Co Debt-to-Equity Related Terms
A Plus Biotechnology Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6918 vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, A Plus Biotechnology Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
A Plus Biotechnology Co Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where A Plus Biotechnology Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A Plus Biotechnology Co (TPE:6918) has a Debt-to-Equity of 0.14 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on A Plus Biotechnology Co and its competitors. This is near median its historical median of 0.13. Over the past decade, A Plus Biotechnology Co's Debt-to-Equity has ranged from 0.05 to 0.25. According to the industry distribution chart, A Plus Biotechnology Co ranks #254 out of 696 companies in the Medical Devices & Instruments industry, placing it in the top 36.5%.
Is A Plus Biotechnology Co's Debt-to-Equity too high?
A Plus Biotechnology Co's current Debt-to-Equity of 0.14 is near median its 10-year median of 0.13. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.25. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. A Plus Biotechnology Co's value of 0.14 is 41.7% below this industry median. Based on the distribution chart, A Plus Biotechnology Co ranks #254 out of 696 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, A Plus Biotechnology Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, A Plus Biotechnology Co ranks #254 out of 696 companies for Debt-to-Equity. This puts A Plus Biotechnology Co in the upper half of its industry. The industry median Debt-to-Equity is 0.24. A Plus Biotechnology Co's value of 0.14 is 41.7% below this benchmark. Historically, A Plus Biotechnology Co's own Debt-to-Equity has ranged from 0.05 to 0.25 over the past decade. While the company's 10-year median is 0.13 vs. the industry median of 0.24, A Plus Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 696 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. A Plus Biotechnology Co's current Debt-to-Equity of 0.14 is 41.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on A Plus Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. A Plus Biotechnology Co's current Debt-to-Equity is 0.14, which is near median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$86.75, compared to a current price of NT$78.00 — trading 10.1% below its estimated fair value. The current Debt-to-Equity is 0.14, which is near median its 10-year median of 0.13 and 41.7% below the Medical Devices & Instruments industry median of 0.24. A Plus Biotechnology Co's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current Debt-to-Equity is 0.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?
Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued.
The current stock price of NT$78.00 is trading 10.1% below its estimated GF Value™ of NT$86.75.
GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.
Key valuation signals for TPE:6918:
Debt-to-Equity: 0.14 (near median its 10-year median of 0.13)
GF Value™: NT$86.75 vs. price of NT$78.00 (10.1% below fair value)
Industry Position: 41.7% below the Medical Devices & Instruments median (#254 of 696)
No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
74GF Score
Get the complete analysis for TPE:6918
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6918 has been successfully added to your 
